Oncology Probes

Acute Myeloid Leukemia (AML)At least 80% of patients with acute myeloid leukemia(AML) have an abnormal karyotype. Cytogeneticanalysis provides some of the strongest prognosticinformation available, predicting outcome of bothremission induction and postremission therapy.Abnormalities which indicate a good prognosisinclude t(8;21), inv(16), and t(15;17). Patients withAML that is characterized by deletions of the longarms or monosomies of chromosomes 5 or 7; bytranslocations or inversions of chromosome 3,t(6;9), t(9;22); or by abnormalities of chromosome11q23 have particularly poor prognoses withchemotherapy.ON AML/ETO t(8;21) Fusiont(8;21)(q22;q22) is the most frequently observed karyotypicabnormality associated with acute myeloid leukemia (AML),especially in FAB M2. As a consequence of the translocationthe AML1 (CBFA2, RUNX1) gene in the 21q22 region isfused to the ETO (MTG8 , RUNX1T) gene in the 8q22 region,resulting in one transcriptionally active gene on the 8qderivativechromosome.The AML/ETO t(8;21)(q21;q22) specific DNA probe is optimizedto detect the reciprocal translocation t(8;21) in a dual-color,dual-fusion assay.Cat.# KBI-10301 AML/ETO t(8;21) FusionRH 120950D21S325490 KB21q22.1570 KBRUNX1T(ETO)8q21.321RUNX1(AML1)600 KB600 KBRH 43237W 10808AMl/ETO t(8;21) Fusion probe hybridized to a normalmetaphase (2R2G).Literature:Sacchi et al, 1995, Genes Chrom Cancer, 79: 97-103.Hagemeijer et al, 1998, Leukemia, 12: 96-101.Ordering information Color Tests Cat#ON AML/ETO t(8;21) Fusion red/green 10 KBI-10301Oncology Probes - Hematology Probes29